STOCK TITAN

REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

REGENXBIO Inc. (RGNX) will participate in two investor conferences: the Barclays Global Healthcare Conference on March 17, 2022, at 11:15 a.m. ET in Miami, FL, and the Morgan Stanley Healthcare Corporate Access Day on March 29, 2022, in Boston, MA. A live webcast of the Barclays presentation will be available on the company's website, with an archived replay accessible for 30 days. REGENXBIO is a clinical-stage biotechnology firm focused on gene therapy, utilizing its NAV Technology Platform for a variety of therapeutic developments.

Positive
  • None.
Negative
  • None.

ROCKVILLE, Md., March 9, 2022 /PRNewswire/ --  REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:

Barclays Global Healthcare Conference
Date: Thursday, March 17, 2022
Location: Loews Miami Beach Hotel, Miami, FL
Presentation: Thursday, March 17, 2022 at 11:15 a.m. ET

Morgan Stanley Healthcare Corporate Access Day
Date: Tuesday, March 29, 2022
Location: Boston Harbor Hotel, Boston, MA

A webcast of the Barclays presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

(PRNewsfoto/REGENXBIO Inc.)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301498746.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO participate in the Barclays Global Healthcare Conference?

REGENXBIO will participate in the Barclays Global Healthcare Conference on March 17, 2022.

What time is REGENXBIO's presentation at the Barclays Global Healthcare Conference?

REGENXBIO's presentation at the Barclays Global Healthcare Conference is at 11:15 a.m. ET.

Where is the Morgan Stanley Healthcare Corporate Access Day taking place?

The Morgan Stanley Healthcare Corporate Access Day will be held at the Boston Harbor Hotel in Boston, MA.

How can I access the webcast of REGENXBIO's presentation?

The webcast of REGENXBIO's presentation can be accessed in the Investors section of their website.

What is the focus of REGENXBIO Inc.?

REGENXBIO focuses on gene therapy, utilizing its NAV Technology Platform to develop treatments in various therapeutic areas.

REGENXBIO Inc.

NASDAQ:RGNX

RGNX Rankings

RGNX Latest News

RGNX Stock Data

510.79M
45.67M
7.39%
92.25%
9.91%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ROCKVILLE